Zsírmáj (MASLD/MASH): vizsgálatok itt: Kína
73 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 156
- Run by
- The United Bio-Technology (Hengqin) Co., Ltd.
See details and how to joinNCT07145151 - 3. fázisNot yet taking people in KínaELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
- Where
- Chengdu, Luoyang, Nanjing, Shanghai
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07850063 · EU 2026-527091-88-00 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang, Hangzhou, Jiaxing, Liaocheng, Luoyang, Nanchang, Nanjing, Ningbo, Ningxia, Pingxiang, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xuzhou, Yanji, Yueyang, Yuncheng, Zhengzhou, Zhenjiang
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Jiaxing, Kunming, Liaocheng, Luoyang, Nanchang, Nanjing, Ningbo, Ningxia, Pingxiang, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Zhengzhou, Zhenjiang
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 1/2. fázisTaking peopleHigh-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease
- Where
- Hangzhou
- Életkor
- 18 év to 74 év
- People
- 74
- Run by
- Li Lab,MD
See details and how to joinNCT07897981 - No phaseTaking peopleiWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 216
- Run by
- Liu Yan
See details and how to joinNCT07237750 - No phaseNot yet taking people in KínaChinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
- Where
- Taiyuan
- Életkor
- 18 év to 79 év
- People
- 25 974
- Run by
- Shanxi Bethune Hospital
See details and how to joinNCT07884903 - 2. fázisNot yet taking people in KínaA Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 120
- Run by
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT07878091 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang, Hangzhou, Jinhua, Liaocheng, Luoyang, Luzhou, Nanchang, Nanjing, Nanyang, Ningbo, Pingxiang, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Xi’an, Yinchuan, Zhoukou
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 886
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07581951 - 4. fázisTaking peoplePre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
- Where
- Beijing, Chengdu, Chongqing, Hefei
- Életkor
- 18 év to 60 év
- People
- 60
- Run by
- West China Hospital
See details and how to joinNCT07718126 - 1. fázisTaking peopleA Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
- Where
- Chengdu
- Életkor
- 18 év to 65 év
- People
- 32
- Run by
- Fujian Shengdi Pharmaceutical Co., Ltd.
See details and how to joinNCT07807059 - No phaseTaking peopleDynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 500
- Run by
- Beijing Friendship Hospital
See details and how to joinNCT03635541 - 1. fázisNot yet taking people in KínaSafety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
- Where
- Beijing, Shanghai, Xiamen, Xi’an
- Életkor
- 18 év to 69 év
- People
- 24
- Run by
- Xiamen Amoytop Biotech Co., Ltd.
See details and how to joinNCT07462455 - 1. fázisTaking peoplePhase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
- Where
- Kunming
- Életkor
- 18 év to 50 év
- People
- 36
- Run by
- Shanghai Minwei Biotechnology Co., Ltd
See details and how to joinNCT07803809 - 2. fázisTaking peopleA Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis
- Where
- Beijing, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 160
- Run by
- Fujian Shengdi Pharmaceutical Co., Ltd.
See details and how to joinNCT07660848 - No phaseNot yet taking people in KínaMetformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD
- Where
- Putian
- Életkor
- 30 év to 60 év
- People
- 84
- Run by
- The 95th Hospital of Putian，Putian, Fujian, China
See details and how to joinNCT07778719 - No phaseTaking peopleDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Where
- Beijing, Chongqing, Qingdao
- Életkor
- 18 év and over
- People
- 3000
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07070362 - No phaseTaking peopleFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
- Where
- Hong Kong
- People
- 1500
- Run by
- Humanity and Health Research Centre
See details and how to joinNCT02863757 - No phaseTaking peopleNonalcoholic Steatohepatitis in Chinese Children
- Where
- Beijing
- Életkor
- 1 év to 18 év
- People
- 400
- Run by
- Humanity and Health Research Centre
See details and how to joinNCT03190538 - No phaseNot yet taking people in KínaCardiovascular Risk in T2DM With MAFLD: A Cohort Study
- Where
- Hanzhou
- Életkor
- 18 év and over
- People
- 7000
- Run by
- The Affiliated Hospital of Hangzhou Normal University
See details and how to joinNCT07706010 - 3. fázisNot yet taking people in KínaA Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 480
- Run by
- Zhejiang Doer Biologics Co., Ltd.
See details and how to joinNCT07693777 - No phaseTaking peopleManagement Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 470
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07682363 - 1/2. fázisTaking peopleDihydroartemisinin for MAFLD
- Where
- Nanjing
- Életkor
- 18 év to 45 év
- People
- 30
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07679542 - No phaseNot yet taking people in KínaLipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 120
- Run by
- Yinzhong Shen
See details and how to joinNCT07640880